Skip to main content
SpringerLink
Log in

The inhibition of HeLa cells proliferation through SPARCL1 mediated by SPP1

  • Original Article
  • Published:
Cytotechnology Aims and scope Submit manuscript

Abstract

Secreted protein acidic and rich in cysteines-like 1 (SPARCL1) is implicated in tumor progression and considered as a tumor suppressor. Aim of the study is to investigate the role of SPARCL1 in the regulation of tumor biology. SPARCL1 expression in human cervical cells was determined through western blot and RT-PCR. The effects of SPARCL1 overexpression on cell proliferation, migration and invasion were evaluated through CCK8 assay, colony formation assay, Wound healing assay and Transwell assay, respectively. The gain function of Secreted phosphor protein 1 (SPP1) was also evaluated in these cell functions. We observed that SPARCL1 expression at protein levels and transcription levels was lower in HeLa cells than that in Ect1/E6E7 cells. When SPARCL1 was overexpressed in HeLa cells, cell proliferation, migration and invasion were greatly repressed. Additionally, SPARCL1 overexpression markedly downregulated SPP1 expression at transcription levels. Mechanistical study revealed that SPP1 overexpression could greatly counteract the effects of SPARCL1 overexpression on the aforementioned cell processes and inhibit the phosphorylation of focal adhesion kinase (FAK) and extracellular regulated protein kinases (ERK). Our findings indicated that HeLa cells overexpressing SPARCL1 showed weaker abilities of proliferation, migration and invasion, and its effects could be neutralized by SPP1 overexpression possibly via FAK/ERK pathway. The relationship of SPARCL1 and SPP1 could help us to further understand the pathogenesis of cervical cancer and SPARCL1/SPP1 could be beneficial therapeutic targets in cervical cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Braz NS, Lorenzi NP, Sorpreso IC, Aguiar LM, Baracat EC, Soares-Júnior JM (2017) The acceptability of vaginal smear self-collection for screening for cervical cancer: a systematic review. Clinics (Sao Paulo) 72:183–187

    Article  Google Scholar 

  • Bradshaw AD (2012) Diverse biological functions of the SPARC family of proteins. Int J Biochem Cell Biol 44:480–488

    Article  CAS  Google Scholar 

  • Wu DM, Shi J, Liu T, Deng SH, Han R, Xu Y (2018) Integrated analysis reveals down-regulation of SPARCL1 is correlated with cervical cancer development and progression. Cancer Biomark 21:355–365

    Article  CAS  Google Scholar 

  • Chen X, Xiong D, Ye L, Yang H, Mei S, Wu J, Chen S, Mi R (2019) SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines. Cancer Chemother Pharmacol 83(4):603–613

    Article  CAS  Google Scholar 

  • Shanthi E, Krishna MH, Arunesh GM, Venkateswara Reddy K, Sooriya Kumar J, Viswanadhan VN (2014) Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review. Expert Opin Ther Pat 24:1077–1100

    Article  CAS  Google Scholar 

  • Liang Y, Zhang T, Shi M, Zhang S, Guo Y, Gao J, Yang X (2019) Low expression of NCOA5 predicts poor prognosis in human cervical cancer and promotes proliferation, migration, and invasion of cervical cancer cell lines by regulating notch3 signaling pathway. J Cell Biochem 120:6237–6249

    Article  CAS  Google Scholar 

  • Zeng J, Ma YX, Liu ZH, Zeng YL (2019) LncRNA SNHG7 contributes to cell proliferation, invasion and prognosis of cervical cancer. Eur Rev Med Pharmacol Sci 23:9277–9285

    CAS  PubMed  Google Scholar 

  • Song JY, Lee JK, Lee NW, Yeom BW, Kim SH, Lee KW (2009) Osteopontin expression correlates with invasiveness in cervical cancer. Aust N Z J Obstet Gynaecol 49:434–438

    Article  Google Scholar 

  • Gagliardi F, Narayanan A, Gallotti AL, Pieri V, Mazzoleni S, Cominelli M, Rezzola S, Corsini M, Brugnara G, Altabella L, Politi LS, Bacigaluppi M, Falini A, Castellano A, Ronca R, Poliani PL, Mortini P, Galli R (2020) Enhanced SPARCL1 expression in cancer stem cells improves preclinical modeling of glioblastoma by promoting both tumor infiltration and angiogenesis. Neurobiol Dis 134:104705

    Article  CAS  Google Scholar 

  • Ma Y, Xu Y, Li L (2018) SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling. Exp Ther Med 16:3195–3201

    PubMed  PubMed Central  Google Scholar 

  • Gagliardi F, Narayanan A, Mortini P (2017) SPARCL1 a novel player in cancer biology. Crit Rev Oncol Hematol 109:63–68

    Article  Google Scholar 

  • Isler SG, Schenk S, Bendik I, Schraml P, Novotna H, Moch H, Sauter G, Ludwig CU (2001) Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers. Int J Oncol 18:521–526

    CAS  PubMed  Google Scholar 

  • Qiang YY, Li CZ, Sun R, Zheng LS, Peng LX, Yang JP, Meng DF, Lang YH, Mei Y, Xie P, Xu L, Cao Y, Wei WW, Cao L, Hu H, Yang Q, Luo DH, Liang YY, Huang BJ, Qian CN (2018) Along with its favorable prognostic role, CLCA2 inhibits growth and metastasis of nasopharyngeal carcinoma cells via inhibition of FAK/ERK signaling. J Exp Clin Cancer Res 37:34

    Article  Google Scholar 

  • Zhang M, Zhao L (2017) CKAP2 promotes ovarian cancer proliferation and tumorigenesis through the FAK-ERK pathway. DNA Cell Biol 36:983–990

    Article  CAS  Google Scholar 

  • Kramerova I, Kumagai-Cresse C, Ermolova N, Mokhonova E, Marinov M, Capote J, Becerra D, Quattrocelli M, Crosbie RH, Welch E, McNally EM, Spencer MJ (2019) Spp1 (osteopontin) promotes TGFβ processing in fibroblasts of dystrophin-deficient muscles through matrix metalloproteinases. Hum Mol Genet 28:3431–3442

    Article  Google Scholar 

  • Mitra A, Chakrabarti J, Banerji A, Das S, Chatterjee A (2006) Culture of human cervical cancer cells, SiHa, in the presence of fibronectin activates MMP-2. J Cancer Res Clin Oncol 132:505–513

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Beijing Tiantan Hospital, Capital Medical University, No. 119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, P.R. China

    Shengpeng Zhang & Limin Feng

  2. Department of Obstetrics and Gynecology, Shunyi Maternal and Children’s Hospital of Beijing Children’s Hospital, Beijing, 101300, P.R. China

    Fengge Zhang

Authors
  1. Shengpeng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fengge Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Limin Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Limin Feng.

Ethics declarations

Conflict of interest

All authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, S., Zhang, F. & Feng, L. The inhibition of HeLa cells proliferation through SPARCL1 mediated by SPP1. Cytotechnology 73, 71–78 (2021). https://doi.org/10.1007/s10616-020-00443-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10616-020-00443-2

Keywords

Search

Navigation